Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) COO Sells $648,888.00 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy Chadwick sold 7,600 shares of the firm’s stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $85.38, for a total transaction of $648,888.00. Following the completion of the transaction, the chief operating officer directly owned 61,202 shares in the company, valued at approximately $5,225,426.76. This represents a 11.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Kymera Therapeutics Stock Performance

KYMR stock opened at $85.40 on Friday. The firm has a market cap of $6.97 billion, a P/E ratio of -23.21 and a beta of 2.28. Kymera Therapeutics, Inc. has a 1 year low of $19.44 and a 1 year high of $103.00. The stock has a 50-day simple moving average of $81.57 and a 200-day simple moving average of $72.16.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). The firm had revenue of $2.87 million during the quarter, compared to analyst estimates of $14.80 million. Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The business’s quarterly revenue was down 60.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.88) EPS. On average, equities research analysts predict that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on KYMR. Citigroup lifted their target price on Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. UBS Group raised their price objective on Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a research note on Tuesday, March 3rd. Morgan Stanley reaffirmed an “overweight” rating and issued a $123.00 price objective on shares of Kymera Therapeutics in a report on Thursday, February 26th. HC Wainwright boosted their target price on shares of Kymera Therapeutics from $84.00 to $134.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Finally, Oppenheimer increased their target price on shares of Kymera Therapeutics from $67.00 to $120.00 and gave the stock an “outperform” rating in a report on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $118.90.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Baker BROS. Advisors LP increased its position in Kymera Therapeutics by 30.2% in the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock worth $673,620,000 after buying an additional 2,005,813 shares during the period. Avoro Capital Advisors LLC boosted its holdings in shares of Kymera Therapeutics by 17.7% during the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after acquiring an additional 1,124,747 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Kymera Therapeutics by 20.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after acquiring an additional 1,061,957 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Kymera Therapeutics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after acquiring an additional 845,922 shares during the period. Finally, Holocene Advisors LP acquired a new stake in shares of Kymera Therapeutics in the 3rd quarter worth about $47,563,000.

Key Stories Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Multiple research firms have raised price targets and reiterated buy/outperform views (Mizuho, Oppenheimer, B. Riley, Leerink, UBS), supporting upside expectations for KYMR. Analyst Upgrades and Targets
• Positive Sentiment: Large institutional holders (Baker Bros., Avoro, Vanguard, Price T. Rowe, BVF) increased positions in recent quarters, signaling continued fund-level conviction in Kymera’s Pegasus degrader platform and pipeline. Institutional Activity
• Neutral Sentiment: Company fundamentals/context: Kymera is a clinical‑stage degrader-focused biotech with a mixed near‑term financial picture (recent quarter missed revenue and EPS estimates). These operational results remain a material background factor for how investors value upcoming clinical and partnership milestones. Earnings and Company Profile
• Negative Sentiment: Director Elena Ridloff sold 4,600 shares on April 1 at an average price of ~$85.42 (disclosed via SEC). Large director sales can create near-term selling pressure or signal personal liquidity needs. Ridloff sale (AmericanBankingNews)
• Negative Sentiment: Additional disclosures show Ridloff sold 7,400 shares on March 31 and the April 1 sale was also filed with the SEC. Total recent Ridloff sales amount to ~12,000 shares across the two trades. Ridloff SEC filing
• Negative Sentiment: COO Jeremy G. Chadwick disclosed multiple sales (7,600 on March 31 and 14,640 on April 1) totaling ~22,240 shares at ~\$85.4 average — a roughly double‑digit percentage reduction in his reported ownership. Senior‑exec selling of this size can weigh on sentiment. Chadwick SEC filing
• Negative Sentiment: Multiple independent reports aggregated these insider trades (InsiderTrades, MarketBeat), increasing transparency but also spotlighting the concentration of recent insider liquidity. InsiderTrades summary

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.